Business Wire

S64

29.9.2022 14:40:15 CEST | Business Wire | Press release

Share
S64 Bolsters Pioneering Team With Strategic Hires Amid Surging Demand for Private Markets Products

S64, the trusted alternatives partner to the world’s leading asset managers and private banks, has today announced a series of strategic hires following a period of rapid growth since its launch in 2020.

S64’s best-in-class team, who worked together for over a decade at Deutsche Bank, has further strengthened its expertise by making a number of appointments from blue-chip institutions to its London office. The business also has plans to advance its footprint across EMEA, Asia and Australia in major global financial hubs.

Strategic hires following rapid growth

Led by founder and CEO Tarun Nagpal, S64’s team has led the way in industry innovation for more than a decade, pioneering the development of alternative platform solutions. The latest additions include Venkata Kota, Head of Client Solutions, formerly of Goldman Sachs and Deutsche Bank; Richard Marland, Head of Operations and Fund Governance, formerly of Deutsche Bank; Tetyana Turek, Business and Project Management, formerly of Deutsche Bank; Mark Slater, Legal Counsel and Compliance, formerly of J.P. Morgan and Simmons & Simmons; and Eve Wachtel, Asia Pacific Distribution, formerly of Deutsche Bank.

The firm’s structuring and solutions team also boasts three new additions, comprising Matteo De Checchi, Dennis Bews and Adam Hooper, from Deutsche Bank, Credit Suisse and Barings respectively.

S64 expects to more than double its 40-strong headcount over the next 12 months across its structuring, distribution, platform and technology expertise.

Tarun Nagpal, CEO of S64, commented:I’m delighted to welcome some of the industry’s leading talent to our firm. Not only do they bring with them deep technical experience, but a track record of market-defining innovation.

We are witnessing a revolution in how private markets are accessed. Our award-winning legacy, unique proposition and market-leading expertise mean we are well-positioned to build upon our impressive growth to date.

As we define a new era in alternative assets, we plan to deepen our expertise through further strategic hires and expand our presence into target markets over the coming year.”

Pipeline of mandates with platinum-level clients

S64 is already the trusted partner of global leaders across private equity, asset management and private wealth having won numerous competitive mandates, including the majority of the top 10 largest private markets managers globally, who have raised over $750 billion USD of funds in the past decade. The firm has built market share at speed with a robust pipeline of new opportunities.

The business is leading the way in industry innovation through the development of an array of novel solutions for clients, including the structuring, delivery and servicing of ELTIFs, UK LTAFs, and open-ended semi-liquid retail products, helping them rapidly scale their offerings.

Tarun Nagpal added: “We’re excited to be working with platinum-level asset managers and private banks, having won a pipeline of highly-coveted mandates which has turbocharged our ambitious growth trajectory.

With our world-class proprietary technology, which services the full lifecycle of alternatives products, our innovative approach is further opening up access to private markets and enabling them to flourish.”

ENDS.

Notes to Editors

  • Global fund manager ranking and fundraising amount according to Preqin’s Fund Managers League Table as of 25.09.22.
  • Preqin calculates top global fund managers based on aggregate capital raised via closed-end commingled funds.
  • Fundraising amount is based on funds raised in the last 10 years.

About S64

S64 is a leading global alternatives solutions business bridging the opportunity in private markets. It works with the world’s first-class asset managers and private banks across private equity, credit, real estate, infrastructure and impact to develop innovative solutions for private banks and wealth managers.

S64’s innovative technology platform offers the full lifecycle management of alternative assets — from structuring and onboarding to financing, as well as secondary market capabilities.

Its team draws on an award-winning legacy in fund and product solutions, digital innovation and international distribution, having pioneered alternative investment platforms for over a decade.

www.s64capital.com | LinkedIn | Twitter

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220929005482/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye